Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CORESTEM, Inc

http://corestem.com/

Latest From CORESTEM, Inc

ITF Pharma Plans October US Roll-Out Of Liquid Riluzole Formulation For ALS

Early engagement with US payers suggests openness to covering a liquid form of riluzole, because the tablet version is proven, but it's impossible to take for many ALS patients, says Italfarmaco subsidiary ITF Pharma.

Rare Diseases Approvals

Treeway Goes To Phase III With ALS Oral Compound

Dutch biotech Treeway has completed its Phase I trial of lead program TW001, an oral formulation of edaravone, for the treatment of amyotrophic lateral sclerosis (ALS) and will now prepare for a pivotal Phase III study.

Clinical Trials Rare Diseases

Korean Pro-Innovation Pricing Steps Draw Mixed Responses

Amid pharma industry’s repeated calls to improve the drug pricing system and properly reflect R&D cost of novel drugs, South Korea released steps that include hiking prices of “global innovative novel drugs” and biomedicines. Response is mixed, with foreign pharmas complaining the steps focus mainly on domestically developed drugs.

South Korea Market Access

Promising Progress With ViroMed, Corestem’s Gene/Cell ALS Therapies

Two South Korean bioventures have highlighted positive clinical progress for their gene- and cell-based novel therapies for ALS at the recent ALS/MND International Symposium in Orlando, with ViroMed unveiling the results of a Phase I/II US study for VM202 and Corestem presenting a Phase II study for Neuronata-R, the world's first commercialized stem cell therapy for the debilitating disease.

BioPharmaceutical Asia Pacific
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • CORESTEM, Inc.
    • Corestem Inc.
UsernamePublicRestriction

Register